Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 66

1.

HBV and HIV/HBV Infected Patients Have Distinct Immune Exhaustion and Apoptotic Serum Biomarker Profiles.

Shata MTM, Abdel-Hameed EA, Rouster SD, Yu L, Liang M, Song E, Esser MT, Shire N, Sherman KE.

Pathog Immun. 2019;4(1):39-65. doi: 10.20411/pai.v4i1.267. Epub 2019 Feb 13.

2.

Improvement in Hepatic Fibrosis Biomarkers Associated With Chemokine Receptor Inactivation Through Mutation or Therapeutic Blockade.

Sherman KE, Abdel-Hameed E, Rouster SD, Shata MTM, Blackard JT, Safaie P, Kroner B, Preiss L, Horn PS, Kottilil S.

Clin Infect Dis. 2019 May 17;68(11):1911-1918. doi: 10.1093/cid/ciy807.

PMID:
30239650
3.

Protective role of IL-22 against Schistosoma mansoni soluble egg antigen-induced granuloma in Vitro.

Nady S, Shata MT, Mohey MA, El-Shorbagy A.

Parasite Immunol. 2017 Jan;39(1). doi: 10.1111/pim.12392. Epub 2016 Dec 12.

4.

Association between IL28B rs12979860 single nucleotide polymorphism and the frequency of colonic Treg in chronically HCV-infected patients.

Mehta M, Hetta HF, Abdel-Hameed EA, Rouster SD, Hossain M, Mekky MA, Khalil NK, Mohamed WA, El-Feky MA, Ahmed SH, Daef EA, El-Mokhtar MA, Abdelwahab SF, Medhat A, Sherman KE, Shata MT.

Arch Virol. 2016 Nov;161(11):3161-9. doi: 10.1007/s00705-016-3015-4. Epub 2016 Aug 20.

5.

Extra-hepatic infection of hepatitis C virus in the colon tissue and its relationship with hepatitis C virus pathogenesis.

Hetta HF, Mekky MA, Khalil NK, Mohamed WA, El-Feky MA, Ahmed SH, Daef EA, Medhat A, Nassar MI, Sherman KE, Shata MT.

J Med Microbiol. 2016 Aug;65(8):703-12. doi: 10.1099/jmm.0.000272. Epub 2016 May 10.

6.

Evaluating the Role of Cellular Immune Responses in the Emergence of HCV NS3 Resistance Mutations During Protease Inhibitor Therapy.

Abdel-Hameed EA, Rouster SD, Ji H, Ulm A, Hetta HF, Anwar N, Sherman KE, Shata MT.

Viral Immunol. 2016 May;29(4):252-8. doi: 10.1089/vim.2015.0093. Epub 2016 Feb 17.

7.

HCV Infection Amplified Th2 Bias and Th17 Responses In Schistosoma-Infected Patients.

Nady S, Ezz A, El-Shorbagy A, Esmat G, Mt S.

Egypt J Immunol. 2016 Jan;23(1):87-96.

PMID:
28502156
8.

HIV-Induced Epigenetic Alterations in Host Cells.

Abdel-Hameed EA, Ji H, Shata MT.

Adv Exp Med Biol. 2016;879:27-38. doi: 10.1007/978-3-319-24738-0_2. Review.

PMID:
26659262
9.

The Beneficial Effect of Cape Gooseberry Juice on Carbon Tetrachloride- Induced Neuronal Damage.

Al-Olayan EM, El-Khadragy MF, Omer SA, Shata MT, Kassab RB, Abdel Moneim AE.

CNS Neurol Disord Drug Targets. 2016;15(3):344-50.

PMID:
26295813
10.

Compartmentalized accumulation of cAMP near complexes of multidrug resistance protein 4 (MRP4) and cystic fibrosis transmembrane conductance regulator (CFTR) contributes to drug-induced diarrhea.

Moon C, Zhang W, Ren A, Arora K, Sinha C, Yarlagadda S, Woodrooffe K, Schuetz JD, Valasani KR, de Jonge HR, Shanmukhappa SK, Shata MT, Buddington RK, Parthasarathi K, Naren AP.

J Biol Chem. 2015 May 1;290(18):11246-57. doi: 10.1074/jbc.M114.605410. Epub 2015 Mar 11.

11.

Association of colonic regulatory T cells with hepatitis C virus pathogenesis and liver pathology.

Hetta HF, Mekky MA, Khalil NK, Mohamed WA, El-Feky MA, Ahmed SH, Daef EA, Nassar MI, Medhat A, Sherman KE, Shata MT.

J Gastroenterol Hepatol. 2015 Oct;30(10):1543-51. doi: 10.1111/jgh.12936.

12.

Modulation of HCV replication after combination antiretroviral therapy in HCV/HIV co-infected patients.

Sherman KE, Guedj J, Shata MT, Blackard JT, Rouster SD, Castro M, Feinberg J, Sterling RK, Goodman Z, Aronow BJ, Perelson AS.

Sci Transl Med. 2014 Jul 23;6(246):246ra98. doi: 10.1126/scitranslmed.3008195.

13.

The protective effect of Physalis peruviana L. against cadmium-induced neurotoxicity in rats.

Abdel Moneim AE, Bauomy AA, Diab MM, Shata MT, Al-Olayan EM, El-Khadragy MF.

Biol Trace Elem Res. 2014 Sep;160(3):392-9. doi: 10.1007/s12011-014-0066-9. Epub 2014 Jul 15.

PMID:
25022246
14.

Evidence of distinct populations of hepatitis C virus in the liver and plasma of patients co-infected with HIV and HCV.

Blackard JT, Ma G, Sengupta S, Martin CM, Powell EA, Shata MT, Sherman KE.

J Med Virol. 2014 Aug;86(8):1332-41. doi: 10.1002/jmv.23968. Epub 2014 Apr 30.

15.

Hepatitis E infection in HIV-infected liver and kidney transplant candidates.

Sherman KE, Terrault N, Barin B, Rouster SD, Shata MT; HIV-TR Investigators.

J Viral Hepat. 2014 Aug;21(8):e74-7. doi: 10.1111/jvh.12233. Epub 2014 Apr 28.

16.

Immune activation in HIV/HCV-infected patients is associated with low-level expression of liver expressed antimicrobial peptide-2 (LEAP-2).

Shata MT, Abdel-Hameed EA, Hetta HF, Sherman KE.

J Clin Pathol. 2013 Nov;66(11):967-75. doi: 10.1136/jclinpath-2013-201581. Epub 2013 Aug 12.

17.

Epigenetic modification of FOXP3 in patients with chronic HIV infection.

Abdel-Hameed EA, Ji H, Sherman KE, Shata MT.

J Acquir Immune Defic Syndr. 2014 Jan 1;65(1):19-26. doi: 10.1097/QAI.0b013e3182a1bca4.

18.

Mutations associated with occult hepatitis B virus infection result in decreased surface antigen expression in vitro.

Martin CM, Welge JA, Rouster SD, Shata MT, Sherman KE, Blackard JT.

J Viral Hepat. 2012 Oct;19(10):716-23. doi: 10.1111/j.1365-2893.2012.01595.x. Epub 2012 Jun 4.

19.

Protective role of humoral immune responses during an outbreak of hepatitis E in Egypt.

Shata MT, Daef EA, Zaki ME, Abdelwahab SF, Marzuuk NM, Sobhy M, Rafaat M, Abdelbaki L, Nafeh MA, Hashem M, El-Kamary SS, Shardell MD, Mikhail NN, Strickland GT, Sherman KE.

Trans R Soc Trop Med Hyg. 2012 Oct;106(10):613-8. doi: 10.1016/j.trstmh.2012.07.004. Epub 2012 Aug 28.

PMID:
22938992
20.

Hepatitis C virus-specific cell-mediated immune responses in children born to mothers infected with hepatitis C virus.

El-Kamary SS, Hashem M, Saleh DA, Abdelwahab SF, Sobhy M, Shebl FM, Shardell MD, Strickland GT, Shata MT.

J Pediatr. 2013 Jan;162(1):148-54. doi: 10.1016/j.jpeds.2012.06.057. Epub 2012 Aug 9.

21.

Low-level HIV infection of hepatocytes.

Kong L, Cardona Maya W, Moreno-Fernandez ME, Ma G, Shata MT, Sherman KE, Chougnet C, Blackard JT.

Virol J. 2012 Aug 9;9:157. doi: 10.1186/1743-422X-9-157.

22.

Letter: pathogenicity of Th17 cells may differ in ulcerative colitis compared with Crohn's disease.

Raza A, Shata MT.

Aliment Pharmacol Ther. 2012 Jul;36(2):204; author reply 205. doi: 10.1111/j.1365-2036.2012.05124.x. No abstract available.

23.

New perspectives of an old cytokine.

Raza A, Shata MT.

Inflamm Bowel Dis. 2013 Mar;19(3):E39-40. doi: 10.1002/ibd.22960. No abstract available.

24.

Th17 cells: interactions with predisposing factors in the immunopathogenesis of inflammatory bowel disease.

Raza A, Yousaf W, Giannella R, Shata MT.

Expert Rev Clin Immunol. 2012 Feb;8(2):161-8. doi: 10.1586/eci.11.96. Review.

25.

HIV variability in the liver and evidence of possible compartmentalization.

Blackard JT, Ma G, Martin CM, Rouster SD, Shata MT, Sherman KE.

AIDS Res Hum Retroviruses. 2011 Oct;27(10):1117-26. doi: 10.1089/AID.2010.0329. Epub 2011 May 4.

26.

Strong hepatitis C virus (HCV)-specific cell-mediated immune responses in the absence of viremia or antibodies among uninfected siblings of HCV chronically infected children.

Hashem M, El-Karaksy H, Shata MT, Sobhy M, Helmy H, El-Naghi S, Galal G, Ali ZZ, Esmat G, Abdelwahab SF, Strickland GT, El-Kamary SS.

J Infect Dis. 2011 Mar 15;203(6):854-61. doi: 10.1093/infdis/jiq123. Epub 2011 Jan 21.

27.

Prevalence of anti-HEV IgM among blood donors in Egypt.

Ibrahim EH, Abdelwahab SF, Nady S, Hashem M, Galal G, Sobhy M, Saleh AS, Shata MT.

Egypt J Immunol. 2011;18(2):47-58.

PMID:
23082470
28.

Pandemic and seasonal H1N1 influenza hemagglutinin-specific T cell responses elicited by seasonal influenza vaccination.

Subbramanian RA, Basha S, Shata MT, Brady RC, Bernstein DI.

Vaccine. 2010 Dec 6;28(52):8258-67. doi: 10.1016/j.vaccine.2010.10.077. Epub 2010 Nov 2.

PMID:
21050903
29.

Age-related changes in magnitude and diversity of cross-reactive CD4+ T-cell responses to the novel pandemic H1N1 influenza hemagglutinin.

Subbramanian RA, Basha S, Brady RC, Hazenfeld S, Shata MT, Bernstein DI.

Hum Immunol. 2010 Oct;71(10):957-63. doi: 10.1016/j.humimm.2010.07.005. Epub 2010 Jul 30.

PMID:
20650295
30.

Risk factors and immune response to hepatitis E viral infection among acute hepatitis patients in Assiut, Egypt.

Eldin SS, Seddik I, Daef EA, Shata MT, Raafat M, Abdel Baky L, Nafeh MA.

Egypt J Immunol. 2010;17(1):73-86.

31.

Genomic variability associated with the presence of occult hepatitis B virus in HIV co-infected individuals.

Martin CM, Welge JA, Shire NJ, Rouster SD, Shata MT, Sherman KE, Blackard JT.

J Viral Hepat. 2010 Aug;17(8):588-97. doi: 10.1111/j.1365-2893.2009.01214.x. Epub 2009 Nov 2.

32.

Genotypic characterization of symptomatic hepatitis E virus (HEV) infections in Egypt.

Blackard JT, Rouster SD, Nady S, Galal G, Marzuuk N, Rafaat MM, Daef E, El Din SS, Purcell RH, Emerson SU, Sherman KE, Shata MT.

J Clin Virol. 2009 Oct;46(2):140-4. doi: 10.1016/j.jcv.2009.07.007. Epub 2009 Aug 3.

33.

Cytokine expression during chronic versus occult hepatitis B virus infection in HIV co-infected individuals.

Martin CM, Welge JA, Shire NJ, Shata MT, Sherman KE, Blackard JT.

Cytokine. 2009 Sep;47(3):194-8. doi: 10.1016/j.cyto.2009.06.005. Epub 2009 Jul 21.

34.

Interleukin-12 is the optimum cytokine to expand human Th17 cells in vitro.

Nady S, Ignatz-Hoover J, Shata MT.

Clin Vaccine Immunol. 2009 Jun;16(6):798-805. doi: 10.1128/CVI.00022-09. Epub 2009 Apr 22.

35.

Hepatitis E virus antibodies in patients with chronic liver disease.

Atiq M, Shire NJ, Barrett A, Rouster SD, Sherman KE, Shata MT.

Emerg Infect Dis. 2009 Mar;15(3):479-81. doi: 10.3201/eid1503.080740.

36.

The mystery of hepatitis E seroprevalence in developed countries: is there subclinical infection due to hepatitis E virus?

Shata MT, Navaneethan U.

Clin Infect Dis. 2008 Oct 15;47(8):1032-4. doi: 10.1086/591971. No abstract available.

37.

Evidence for protection against chronic hepatitis C virus infection in chimpanzees by immunization with replicating recombinant vaccinia virus.

Youn JW, Hu YW, Tricoche N, Pfahler W, Shata MT, Dreux M, Cosset FL, Folgori A, Lee DH, Brotman B, Prince AM.

J Virol. 2008 Nov;82(21):10896-905. doi: 10.1128/JVI.01179-08. Epub 2008 Aug 27.

38.

Hepatitis E and pregnancy: understanding the pathogenesis.

Navaneethan U, Al Mohajer M, Shata MT.

Liver Int. 2008 Nov;28(9):1190-9. doi: 10.1111/j.1478-3231.2008.01840.x. Epub 2008 Jul 25. Review.

39.

Effect of low-dose IL-2 immunotherapy on frequency and phenotype of regulatory T cells and NK cells in HIV/HCV-coinfected patients.

Velilla PA, Shata MT, Lages CS, Ying J, Fichtenbaum CJ, Chougnet C.

AIDS Res Hum Retroviruses. 2008 Jan;24(1):52-61. doi: 10.1089/aid.2007.0180.

PMID:
18275348
40.

Acute hepatitis C virus infection: a chronic problem.

Blackard JT, Shata MT, Shire NJ, Sherman KE.

Hepatology. 2008 Jan;47(1):321-31. Review. No abstract available. Erratum in: Hepatology. 2008 Feb;47(2):769.

41.

Characterization of hepatitis E-specific cell-mediated immune response using IFN-gamma ELISPOT assay.

Shata MT, Barrett A, Shire NJ, Abdelwahab SF, Sobhy M, Daef E, El-Kamary SS, Hashem M, Engle RE, Purcell RH, Emerson SU, Strickland GT, Sherman KE.

J Immunol Methods. 2007 Dec 1;328(1-2):152-61. Epub 2007 Sep 19.

42.

Attempted therapeutic immunization in a chimpanzee chronic HBV carrier with a high viral load.

Shata MT, Pfahler W, Brotman B, Lee DH, Tricoche N, Murthy K, Prince AM.

J Med Primatol. 2006 Jun;35(3):165-71.

43.

gC1qR expression in chimpanzees with resolved and chronic infection: potential role of HCV core/gC1qR-mediated T cell suppression in the outcome of HCV infection.

Yao ZQ, Shata MT, Tricoche N, Shan MM, Brotman B, Pfahler W, Hahn YS, Prince AM.

Virology. 2006 Mar 15;346(2):324-37. Epub 2005 Dec 20. Retraction in: Virology. 2007 Nov 25;368(2):432.

44.

Sustained E2 antibody response correlates with reduced peak viremia after hepatitis C virus infection in the chimpanzee.

Youn JW, Park SH, Lavillette D, Cosset FL, Yang SH, Lee CG, Jin HT, Kim CM, Shata MT, Lee DH, Pfahler W, Prince AM, Sung YC.

Hepatology. 2005 Dec;42(6):1429-36.

PMID:
16317673
45.

Protection against chronic hepatitis C virus infection after rechallenge with homologous, but not heterologous, genotypes in a chimpanzee model.

Prince AM, Brotman B, Lee DH, Pfahler W, Tricoche N, Andrus L, Shata MT.

J Infect Dis. 2005 Nov 15;192(10):1701-9. Epub 2005 Oct 6.

PMID:
16235167
46.

Exposure to hepatitis C virus induces cellular immune responses without detectable viremia or seroconversion.

Al-Sherbiny M, Osman A, Mohamed N, Shata MT, Abdel-Aziz F, Abdel-Hamid M, Abdelwahab SF, Mikhail N, Stoszek S, Ruggeri L, Folgori A, Nicosia A, Prince AM, Strickland GT.

Am J Trop Med Hyg. 2005 Jul;73(1):44-9.

PMID:
16014830
47.

Schistosoma infection inhibits cellular immune responses to core HCV peptides.

Farid A, Al-Sherbiny M, Osman A, Mohamed N, Saad A, Shata MT, Lee DH, Prince AM, Strickland GT.

Parasite Immunol. 2005 May;27(5):189-96.

48.

The immunologic basis for hepatitis C infection.

Sun J, Li K, Shata MT, Chan TS.

Curr Opin Gastroenterol. 2004 Nov;20(6):598-602.

PMID:
15703689
49.

Hepatitis C virus replication kinetics in chimpanzees with self-limited and chronic infections.

Prince AM, Pawlotsky JM, Soulier A, Tobler L, Brotman B, Pfahler W, Lee DH, Li L, Shata MT.

J Viral Hepat. 2004 May;11(3):236-42.

PMID:
15117325
50.

Virus dynamics and immune responses during treatment in patients coinfected with hepatitis C and HIV.

Talal AH, Shata MT, Markatou M, Dorante G, Chadburn A, Koch R, Neumann AU, Ribeiro RM, Perelson AS.

J Acquir Immune Defic Syndr. 2004 Feb 1;35(2):103-13. Erratum in: J Acquir Immune Defic Syndr. 2004 May 1;36(1):648.

PMID:
14722440

Supplemental Content

Loading ...
Support Center